$5.62
Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?
Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052
Overview
52-week range
$1.34
$5.15
100% of range
Avg surprise (last 3)
+11.9%
Avg reaction (last 2)
+3.2%
100% positive
Latest IV / EM
132%
EM ±30.2% · $6 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.15 | $-0.16 | +6.2% | -25.0% | +1.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.12 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.13 | $-0.13 | 0.0% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.12 | $-0.17 | +29.4% | — | +4.8% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.11 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.15 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.24 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.41 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.42 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.16 | -$0.13 | -23.1% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $395,000 | — | $538,000 | $515,000 | $506,000 | — | $654,000 | $624,000 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-22M | — | $-17M | $-18M | $-18M | — | $-10M | $-13M |
| Net income | $-20M | — | $-15M | $-15M | $-15M | — | $-8M | $-11M |
| EPS (diluted) | $-0.15 | — | $-0.12 | $-0.13 | $-0.12 | — | $-0.11 | $-0.15 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $29M | $20M | $25M | $25M | $30M | $25M | $48M | $23M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $110M | $96M | $101M | $104M | $109M | $126M | $132M | $118M |
| Total assets | $199M | $160M | $176M | $189M | $198M | $220M | $182M | $161M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $55M | $57M | $55M | $57M | $54M | $65M | $52M | $27M |
| Total equity | $144M | $103M | $120M | $132M | $144M | $156M | $130M | $134M |